Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib

Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after cessation of nintedanib. Nintedanib may induce left...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Ryosuke, Tomishima, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017142/
https://www.ncbi.nlm.nih.gov/pubmed/32082576
http://dx.doi.org/10.1002/rcr2.533
_version_ 1783497134955298816
author Imai, Ryosuke
Tomishima, Yutaka
author_facet Imai, Ryosuke
Tomishima, Yutaka
author_sort Imai, Ryosuke
collection PubMed
description Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after cessation of nintedanib. Nintedanib may induce left ventricular dysfunction, and early recognition is important since this condition is potentially reversible.
format Online
Article
Text
id pubmed-7017142
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-70171422020-02-20 Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib Imai, Ryosuke Tomishima, Yutaka Respirol Case Rep Case Reports Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after cessation of nintedanib. Nintedanib may induce left ventricular dysfunction, and early recognition is important since this condition is potentially reversible. John Wiley & Sons, Ltd 2020-02-13 /pmc/articles/PMC7017142/ /pubmed/32082576 http://dx.doi.org/10.1002/rcr2.533 Text en © 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Imai, Ryosuke
Tomishima, Yutaka
Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
title Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
title_full Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
title_fullStr Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
title_full_unstemmed Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
title_short Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
title_sort left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017142/
https://www.ncbi.nlm.nih.gov/pubmed/32082576
http://dx.doi.org/10.1002/rcr2.533
work_keys_str_mv AT imairyosuke leftventriculardysfunctioninanidiopathicpulmonaryfibrosispatientonnintedanib
AT tomishimayutaka leftventriculardysfunctioninanidiopathicpulmonaryfibrosispatientonnintedanib

Ejemplares similares